

~~We e~~Claims:

1. A compound represented by formula I or II:



(I) or



(II),

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is hydrogen, halogen, amino, hydroxyl, alkoxy, or alkylthio;

V and W are each independently CR^a or N;

each R^a independently is hydrogen, halogen, nitro, cyano, amino, hydroxyl, alkoxy, alkylthio, or alkyl;

X is CR^b or N;

R^b is hydrogen, halogen, nitro, cyano, amino, hydroxyl, alkoxy, alkylthio, alkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;

each U independently is N or CR^c;

each R^c independently is hydrogen, halogen, alkyl, or alkoxy;

ring Z^1 is a five- or six-membered aryl or heteroaryl;

ring Z^2 is a five- or six-membered heterocycle;



each R^2 independently is halogen, nitro, cyano, amino, acylamino, amido, hydroxyl, alkoxy, alkylthio, acyl, amidino, azido, carbamoyl, carboxyl, carboxyester, guanidine, haloalkyl, haloalkoxy, heteroalkyl, imino, oxime, phosphonate, dialkylphosphine oxide, sulfonyl, sulfonamido, sulfonyl urea, sulfinyl, sulfinic acid, sulfonic acid, thiocyanate, thiocarbonyl, alkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or two vicinal R^2, together with the intervening carbon atoms to which they attach, combine to form a 5- or 6-membered carbocycle, 5- or 6-membered heterocycle, 5- or 6-membered aryl, or 5- or 6-membered heteroaryl;

n is 0 or an integer selected from 1-4, as valency permits;

each R^6 independently is halogen, nitro, cyano, amino, acylamino, amido, hydroxyl, oxo, carboxyl, alkoxy, alkylthio, acyl, amidino, azido, carbamoyl, carboxyl, carboxyester,

guanidine, haloalkyl, haloalkoxy, heteroalkyl, imino, oxime, phosphonate, dialkylphosphine oxide, sulfonyl, sulfonamido, sulfonyl urea, sulfinyl, sulfinic acid, sulfonic acid, thiocyanate, thiocarbonyl, alkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or any two R^6, together with the intervening carbon atom(s) to which they attach, combine to form a carbocycle or heterocycle;

q is 0 or an integer selected from 1-4, as valency permits;



R^3 is  or ;

M is $N(R^8)_3$, $N(R^8)_2$, OR^8 or SR^8;

each R^8 is independently hydrogen, alkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; and

R^{3a} and R^{3b} independently are hydrogen, alkyl, acyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or R^{3a} and R^{3b}, together with the boron atom and the two intervening oxygen atoms that separate them, combine to form a monocyclic or polycyclic heterocyclyl; or R^{3a}, R^{3b}, and M, together with the boron atom and the intervening oxygen atoms, combine to form a polycyclic heterocycle.

2. The compound of claim 1, wherein the compound is represented by formula I-a or II-a:

 (I-a) or  (II-a).

3. The compound of claim 1 or 2, wherein R^1 is hydroxyl or C_{1-3} alkoxy, or wherein -

~~4. The compound of claim 1 or 2, wherein~~ R^1 is amino and is preferably -

~~5. The compound of claim 4, wherein R^1 is~~ $-NH_2$ or $-NHCH_3$.

64. The compound of any one of claims 1 to 53, wherein each R^2 independently is halogen, nitro, cyano, amino, acylamino, amido, hydroxyl, alkoxy, alkylthio, phosphonate, dialkylphosphine oxide, alkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or two vicinal R^2, together with the intervening carbon atoms to which they attach, combine to form a 5- or 6-membered carbocycle, 5- or 6-membered heterocycle, 5- or 6-membered aryl, or 5- or 6-membered heteroaryl, preferably .

7. The compound of any one of claims 1 to 5, wherein each R^2 independently is halogen, cyano, amino, acylamino, amido, hydroxyl, alkoxy, dialkylphosphine oxide, haloalkyl, sulfonyl, alkyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

8. The compound of any one of claims 1 to 5, wherein each R^2 independently is halogen, cyano, amino, acylamino, amido, hydroxyl, alkoxy, dialkylphosphine oxide, alkyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaralkyl or heteroaryl.

95. The compound of any one of claims 1 to 53, wherein:

each R^2 independently is -F, cyano, $-C(O)N(R^4)_2$, $-N(H)C(O)R^4$, $-OCF_3$, $-OCH_2C(O)N(R^4)_2$, $-O(CH_2CH_2O)_rR^4$, $-CF_3$, $-CHF_2$, $-OCH_3$, $-P(=O)(CH_3)_2$, $-CH_2COOH$, $-CH_3$, $-C_2H_5$, cyclopropyl, tetrahydropyranyl, 1,1-dioxo-1,2,5-thiadiazolidinyl or pyridinyl; wherein

R^4 is alkyl, alkenyl, carbocyclyl, heterocyclyl, aryl or heteroaryl; or two R^4, together with the nitrogen atom, complete a 5- to 6-membered heterocycle; and

r is an integer selected from 1-6, or .

10. The compound of any one of claims 1 to 5,

wherein:

each R^2 independently is -F, cyano, $-N(H)C(O)R^4$, $-OCF_3$, $-OCH_2C(O)N(R^4)_2$, $-O(CH_2CH_2O)_rR^4$, $-CF_3$, $-CHF_2$, $-OCH_3$, $-P(=O)(CH_3)_2$, $-CH_3$, $-C_2H_5$, cyclopropyl, tetrahydropyranyl, 1,1-dioxo-1,2,5-thiadiazolidinyl or pyridinyl; wherein

R^4 is alkyl, alkenyl, carbocyclyl, heterocyclyl, aryl or heteroaryl; and

r is an integer selected from 1-6, optionally .

~~11. The compound of claim any one of claims 1 to 10,~~

~~-~~wherein each R^2 is independently substituted with deuterium.

~~12~~6. The compound of any one of claims 1-~~5~~3, wherein two vicinal R^2, together with the intervening carbon atoms to which they attach, combine to form a 5- or 6-membered carbocycle, 5- or 6-membered heterocycle, 5- or 6-membered aryl ring, or 5- or 6-membered heteroaryl ring, preferably~~.~~

~~13. The compound of claim 12,~~ wherein two vicinal R^2, together with the intervening carbon atoms to which they attach, combine to form a 5- or 6-membered heteroaryl ring, optionally~~.~~

~~14. The compound of claim 13,~~ wherein the 5- or 6-membered heteroaryl ring is furan, pyrazole, indazole, or oxazole, or~~.~~

~~15. The compound of claim 12,~~

wherein two vicinal R^2, together with the intervening carbon atoms to which they attach, combine to form a 5- or 6-membered heterocycle, optionally~~.~~

~~16. The compound of claim 15,~~ wherein the 5- or 6-membered heterocycle is tetrahydrofuran or tetrahydropyran.

~~17~~7. The compound of any one of claims 1 to 6~~16~~, wherein each R^a independently is hydrogen, halogen, amino, hydroxyl, alkoxy or alkyl, preferably~~.~~

~~18. The compound of claim 17,~~ wherein R^a is hydrogen.

~~19~~8. The compound of any one of claims 1 to ~~18~~8, wherein R^b is hydrogen, halogen, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, preferably~~;~~

~~20. The compound of claim 19,~~ wherein R^b is hydrogen, C_1-C_3 alkyl, or cyclopropyl, preferably methyl.

~~2~~19. The compound of any one of claims 1 to ~~20~~8, wherein each R^c independently is hydrogen, halogen, or alkyl.

~~22~~10. The compound of any one of claims 1 to 21, wherein one of V, W, and X is N, or ~~.~~

~~23. The compound of any one of claims 1 to 21,~~ wherein two of V, W, and X are N, or~~.~~

~~24. The compound of claim 21,~~ wherein W and X are N and V is CR^a, optionally~~.~~

~~25. The compound of claim 24,~~ wherein R^a is hydrogen.

~~26~~11. The compound of claim ~~23~~10, wherein V and W are N and X is CR^b, preferably~~.~~

~~27. The compound of claim 26,~~ wherein R^b is methyl.


~~28~~12. The compound of any one of claims 1 to ~~27~~11, wherein U is CR^c, optionally~~.~~


~~29. The compound of any one of claims 1 to 28,~~ wherein R^c is hydrogen, F, methyl, methoxy, or Cl.

~~30~~13. The compound of any one of claims 1 to ~~29~~12, wherein ring Z^1 is phenyl or a five- or six-membered heteroaryl.

~~31. The compound of claim 30, wherein ring Z^1 is phenyl.~~

~~32~~14. The compound of claim ~~31~~13, wherein the compound is represented by formula I-b or II-b:



(I-b) or



(II-b).


~~33~~15. The compound of claim ~~30~~13, wherein ring Z^1 is a five- or six-membered heteroaryl, optionally~~.~~

~~34. The compound of claim 33,~~ wherein ring Z^1 is a pyrazolyl or ~~.~~

~~35. The compound of claim 33, wherein ring Z^1 is~~ a pyridinyl.

~~36~~16. The compound of claim ~~35~~15, wherein the compound is a compound represented by formula I-c or II-c:





(I-c) or


(II-c).

~~37. The compound of any one of claims 1 to 36, wherein the compound is represented by formula I, I-a, I-b or I-c.~~


















~~38.~~17. The compound of ~~claim 36~~any one of claims 1-16, wherein the compound is represented by formula I-c-1 or I-c-2:







(I-c-1) or




(I-c-2),

wherein R^{2a} is alkyl, aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl.


~~39~~18. The compound of claim ~~38~~17, wherein R^{2a} is methyl, difluoromethyl, $-CF_2CHF_2$, $-CHFCF_3$, $-CH_2CF_3$, $-(CH_2CH_2O)_2CH_3$, , , , , , , , , , , , , , , , , , , or , optionally ~~,~~

~~40. The compound of claim 38,~~ wherein R^{2a} is methyl, difluoromethyl, , , , or , or~~,~~

~~41. The compound of claim 38,~~ wherein R^{2a} is

 or , wherein m is an integer from 2 to 6.

~~42~~19. The compound of any ~~one of claims 37 to 41~~claim 17 or 18, wherein R^3 is




optionally wherein

~~43. The compound of claim 42, wherein~~ R^{3a} and R^{3b} independently are hydrogen, alkyl, acyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl, preferably.

~~44. The compound of claim 42,~~ wherein R^{3a} and R^{3b} are hydrogen. or

~~45. The compound of claim 42,~~ wherein R^{3a} and R^{3b}, together with the boron atom and the two intervening oxygen atoms that separate them, combine such that R^3 is a heterocyclyl, optionally wherein.

~~46~~20. The compound of claim ~~45~~19, wherein R^3 is


,

wherein:


each R^5 independently is halogen, nitro, cyano, amino, acylamino, amido, hydroxyl, oxo, carboxy, alkoxy, alkylthio, alkyl (e.g., carboxymethyl), aralkyl, heteroaralkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; or any two R^5, independently, together with the intervening carbon atom(s) to which they attach, combine to form a carbocycle or heterocycle; and

p is 0 or an integer selected from 1-6, as valency permits, optionally.


~~47. The compound of claim 46,~~ wherein R^3 is



48. The compound of claim 47, wherein R^3 is




4921. The compound of any one of claims 37 to 41 claim 17 or 18, wherein R^3 is



; and

R^{3a}, R^{3b}, and M, together with the boron atom and the intervening atoms, combine such that R^3 is a polycyclic heterocycle, optionally.

50. The compound of claim 49, wherein R^3 is




, wherein R^d is H or C_1-C_4 alkyl, preferably.

51. The compound of claim 50, wherein R^d is H or methyl.


~~52. The compound of claim 50, wherein R^4 is H.~~

~~53. The compound of any one of claims 1 to 36, wherein the compound is represented by formula II, II-a, II-b or II-c.~~


~~54~~22. The compound of any one of claims 1-16~~claim 32~~, wherein the compound is represented by formula II-b-1,II-b-2, or II-b-3:



(II-b-1),



(II-b-2), or




(II-b-3).


~~55. The compound of claim 54~~optionally~~,~~ wherein each R^6 independently is halogen, alkyl, carbocyclyl, allyl, or oxo, or optionally~~.~~

~~56. The compound of claim 54,~~ wherein each R^6 independently is halogen, alkyl, or oxo.

~~57~~23. The compound of claim ~~54~~22, wherein ring Z^2 is




58. ~~The compound of claim 54, wherein ring Z^2 is~~















































59. ~~The compound of any one of claims 53 to 58, wherein R^{3a} is hydrogen.~~




60. ~~The compound of any one of claims 53 to 58, wherein R^{3a} is methyl.~~



~~61~~24. The compound of any one of claims 1 to ~~58~~23, wherein the compound is selected from:





















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,



















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

, ,

,

,

,

,

,

,

,

,

,

,

,

,






















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,




















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,














,


,

,

,




,



,

,

,

,

,

,

,

,

,

,

,

,


,

,








,

,

,

,

,

,

,

,

,


,

,

,

,

,

, and

,

or a pharmaceutically acceptable salt thereof.

~~62. The compound of any one of claims 1 to 59, wherein the pharmaceutically acceptable salt is a formic acid salt, methanesulfonic acid salt, ethane sulfonic acid salt, or maleic acid salt.~~

~~63~~25. A pharmaceutical composition, comprising the compound of any one of claims 1 to ~~62~~ 24 and a pharmaceutically acceptable excipient.

26. A compound of any one of claims 1-24 for use in treating a disease or condition associated with complement activation.

27. Use of a compound of any one of claims 1-24 in the manufacture of a medicament for treating a disease or condition associated with complement activation.

~~64. A method of treating a disease or condition associated with complement activation in an individual in need thereof, comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 62 or the composition of claim 63.~~

~~65~~28. The ~~method~~ compound of claim ~~64~~26 or the use of claim 27, wherein the disease or condition associated with complement activation is selected from a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease, and a metabolic disorder.

~~66~~29. The ~~method~~ compound or use of claim 28~~of claim 64 or 65~~, wherein the disease or condition associated with complement activation is chosen from Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive multiple sc~~h~~lerosis, glaucoma, myotonic dystrophy, Guillain-Barre´ syndrome, Myasthenia Gravis, spinal muscular atrophy, Down syndrome, Parkinson's disease, Huntington's disease, traumatic brain injury, epilepsy, frontotemporal dementia, diabetes, obesity, atherosclerosis, rheumatoid arthritis, acute respiratory distress syndrome, pemphigus, pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, immune-mediated necrotizing myopathy, vitiligo, paraneoplastic syndromes, a vasculitis disease, hypocomplementemic urticarial vasculitis, chronic spontaneous urticaria, remote tissue injury after ischemia and reperfusion, complement activation during cardiopulmonary bypass surgery, dermatomyositis, lupus nephritis and resultant glomerulonephritis and vasculitis, kidney fibrosis, systemic lupus erythematosus, Hashimoto's thyroiditis, Addison's disease, Celiac disease, Crohn's disease, pernicious anemia, chronic idiopathic demyelinating polyneuropathy, multifocal motor neuropathy, heparin-induced thrombocytopenia, idiopathic thrombocytopenic purpura, cardioplegia-induced coronary endothelial dysfunction, type II membranoproliferative glomerulonephritis, IgA nephropathy, acute renal failure, cryoglobulemia, antiphospholipid syndrome, chronic open-angle glaucoma, acute closed angle glaucoma, macular degenerative diseases, wet age-related macular degeneration, dry age-related macular degeneration, geographic atrophy, choroidal

neovascularization, uveitis, diabetic retinopathy, ischemia-related retinopathy, endophthalmitis, intraocular neovascular disease, diabetic macular edema, pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, neuromyelitis optica, central retinal vein occlusion , corneal neovascularization, retinal neovascularization, Leber's hereditary optic neuropathy, optic neuritis, Behcet's retinopathy, ischemic optic neuropathy, retinal vasculitis, ANCA vasculitis, Wegener's granulomatosis, Purtscher retinopathy, Sjogren's dry eye disease, sarcoidosis, temporal arteritis, polyarteritis nodosa, allo-transplantation, hyperacute rejection, hemodialysis, chronic occlusive pulmonary distress syndrome, asthma, aspiration pneumonia, immune thrombocytopenia, autoimmune hemolytic anemia, cold agglutinin disease, warm autoimmune hemolytic anemia and coronary artery disease.

~~67. The method of any one of claims 64 to 65, wherein the disease or condition is a neurodegenerative disorder.~~

~~68. The method of claim 67, wherein the neurodegenerative disorder is associated with loss of synapses or loss of nerve connections.~~

~~69. The method of claim 68, wherein the neurodegenerative disorder is associated with synapse loss that is dependent on C1q, C1 complex, CR1, C3, CR3, C4, or CR4.~~

~~70. The method of claim 68, wherein the neurodegenerative disorder is associated with activation or dysregulation of C1s.~~

~~71. The method of claim 68, wherein the neurodegenerative disorder is associated with pathological activity-dependent synaptic loss.~~

~~72. The method of claim 68, wherein the neurodegenerative disorder is associated with synapse phagocytosis by microglia.~~

~~73. The method of any one of claims 67 to 72, wherein the neurodegenerative disorder is selected from Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive multiple schlerosis, glaucoma, myotonic dystrophy, Guillain-Barre´ syndrome, Myasthenia~~

~~Gravis, spinal muscular atrophy, Down syndrome, Parkinson's disease, Huntington's disease, traumatic brain injury, epilepsy, wet age-related macular degeneration, dry age-related macular degeneration, geographic atrophy, and frontotemporal dementia.~~

~~74. The method of claim 73, wherein the neurodegenerative disorder is selected from Guillain-Barre´ syndrome, Huntington's disease, amyotrophic lateral sclerosis, and geographic atrophy.~~

~~75. The method of any one of claims 64 to 66, wherein the disease or condition is an inflammatory disease, an autoimmune disease, a metabolic disorder, or an ophthalmic disease.~~

~~76. The method of claim 75, wherein the inflammatory disease, autoimmune disease, metabolic disorder, or ophthalmic disease is associated with activation or dysregulation of C1s.~~

~~77. The method of claim 75 or 76, wherein the inflammatory disease, autoimmune disease, metabolic disorder, or ophthalmic disease is selected from diabetes, obesity, atherosclerosis, rheumatoid arthritis, acute respiratory distress syndrome, pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid, remote tissue injury after ischemia and reperfusion, complement activation during cardiopulmonary bypass surgery, dermatomyositis, pemphigus, lupus nephritis and resultant glomerulonephritis and vasculitis, kidney fibrosis, systemic lupus erythematosus, Hashimoto's thyroiditis, Addison's disease, Celiac disease, Crohn's disease, pernicious anaemia, immune-mediated necrotizing myopathy, vitiligo, paraneoplastic syndromes, a vasculitis disease, hypocomplementemic urticarial vasculitis, chronic spontaneous urticaria, chronic idiopathic demyelinating polyneuropathy, polymyalgia rheumatica, multifocal motor neuropathy, immune thrombocytopenia, heparin-induced thrombocytopenia, idiopathic thrombocytopenic purpura, cardioplegia-induced coronary endothelial dysfunction, type II membranoproliferative glomerulonephritis, IgA nephropathy, acute renal failure, cryoglobulemia, antiphospholipid syndrome, chronic open-angle glaucoma, acute closed-angle glaucoma, macular degenerative diseases, wet age-related macular degeneration, dry age-related macular degeneration, geographic atrophy, choroidal neovascularization, uveitis, diabetic retinopathy, ischemia-related retinopathy, endophthalmitis, intraocular neovascular disease, diabetic macular edema, pathological myopia, von Hippel-Lindau disease, histoplasmosis of the eye, neuromyelitis optica,~~

~~central retinal vein occlusion , corneal neovascularization, retinal neovascularization, Leber's hereditary optic neuropathy, optic neuritis, Behcet's retinopathy, ischemic optic neuropathy, retinal vasculitis, ANCA vasculitis, Wegener's granulomatosis, Purtscher retinopathy, Sjogren's dry eye disease, sarcoidosis, temporal arteritis, polyarteritis nodosa, multiple sclerosis, progressive multiple schlerosis, allo-transplantation, hyperacute rejection, hemodialysis, chronic occlusive pulmonary distress syndrome, asthma, aspiration pneumonia, immune thrombocytopenia, autoimmune hemolytic anemia, cold agglutinin disease, warm autoimmune hemolytic anemia, and coronary artery disease.~~

~~78. The method of claim 77, wherein the disease or condition is selected from myasthenia gravis, Diabetes mellitus type 1, Hashimoto's thyroiditis, Addison's disease, Coeliac disease, Crohn's disease, pernicious anaemia, pemphigus vulgaris, vitiligo, autoimmune hemolytic anemias, cold agglutinin disease, warm autoimmune hemolytic anemia, paraneoplastic syndromes, a vasculitis disease, hypocomplementemic urticarial vasculitis, chronic spontaneous urticaria, polymyalgia rheumatica, temporal arteritis, Wegener's granulomatosis, immune thrombocytopenia, wet age-related macular degeneration, dry age-related macular degeneration, geographic atrophy, lupus nephritis, systemic lupus erythematosus and multifocal motor neuropathy.~~

~~79. The method of claim 78, wherein the disease or condition is selected from cold agglutinin disease, warm autoimmune hemolytic anemia, geographic atrophy, lupus nephritis and multifocal motor neuropathy.~~

~~80. A method of inhibiting activated C1s, comprising contacting the activated C1s with a compound of any one of claims 1 to 62 or a composition of claim 63.~~

~~81. The method of claim 80, wherein contacting the C1s with the compound comprises administering the compound to an individual.~~